| scholarly article | Q13442814 |
| P50 | author | Andrzej M. Kierzek | Q41117993 |
| Nick Plant | Q42717895 | ||
| J Bernadette Moore | Q47158643 | ||
| P2093 | author name string | Ciarán P Fisher | |
| P2860 | cites work | Computational prediction of human metabolic pathways from the complete human genome | Q21092879 |
| Finishing the euchromatic sequence of the human genome | Q22122488 | ||
| A protocol for generating a high-quality genome-scale metabolic reconstruction | Q24603373 | ||
| GENCODE: the reference human genome annotation for The ENCODE Project | Q24608743 | ||
| Systems biology and the virtual physiological human | Q24653792 | ||
| Global reconstruction of the human metabolic network based on genomic and bibliomic data | Q24677060 | ||
| Tuberculosis presenting as immune thrombocytopenic purpura | Q24791974 | ||
| Proteomics and Systems Biology: Current and Future Applications in the Nutritional Sciences | Q26829598 | ||
| Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges | Q27023893 | ||
| The complete genome sequence of Escherichia coli K-12 | Q27860542 | ||
| What is flux balance analysis? | Q28275348 | ||
| SurreyFBA: a command line tool and graphics user interface for constraint-based modeling of genome-scale metabolic reaction networks | Q28300416 | ||
| Optimization of stress response through the nuclear receptor-mediated cortisol signalling network | Q28397689 | ||
| In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators | Q28471679 | ||
| The signaling petri net-based simulator: a non-parametric strategy for characterizing the dynamics of cell-specific signaling networks | Q28472336 | ||
| Context-specific metabolic networks are consistent with experiments | Q28472711 | ||
| Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model | Q28475693 | ||
| Building disease-specific drug-protein connectivity maps from molecular interaction networks and PubMed abstracts | Q28475789 | ||
| Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT | Q28483779 | ||
| KEGG for integration and interpretation of large-scale molecular data sets | Q29547277 | ||
| Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey | Q29614468 | ||
| A community-driven global reconstruction of human metabolism. | Q29614690 | ||
| COPASI--a COmplex PAthway SImulator | Q29617467 | ||
| Dynamic analysis of integrated signaling, metabolic, and regulatory networks | Q30441717 | ||
| Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis | Q30479092 | ||
| Prediction and validation of cell alignment along microvessels as order principle to restore tissue architecture in liver regeneration | Q30495068 | ||
| Nutritional systems biology modeling: from molecular mechanisms to physiology | Q30943969 | ||
| New insights into functional aspects of liver morphology | Q30986309 | ||
| Compartmentalization of the Edinburgh Human Metabolic Network | Q30986319 | ||
| Rapidly exploring structural and dynamic properties of signaling networks using PathwayOracle | Q33361469 | ||
| A detailed genome-wide reconstruction of mouse metabolism based on human Recon 1. | Q33722800 | ||
| iAB-RBC-283: A proteomically derived knowledge-base of erythrocyte metabolism that can be used to simulate its physiological and patho-physiological states | Q33958875 | ||
| A multi-tissue type genome-scale metabolic network for analysis of whole-body systems physiology | Q34063123 | ||
| Reconstruction and analysis of human heart-specific metabolic network based on transcriptome and proteome data | Q34068001 | ||
| Regulation of Gene Expression in Flux Balance Models of Metabolism | Q34101809 | ||
| HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology | Q34240836 | ||
| Integration of clinical data with a genome-scale metabolic model of the human adipocyte | Q34334051 | ||
| Insight into human alveolar macrophage and M. tuberculosis interactions via metabolic reconstructions | Q34344292 | ||
| Reconstruction of cellular signalling networks and analysis of their properties | Q34385115 | ||
| CardioNet: a human metabolic network suited for the study of cardiomyocyte metabolism | Q34396816 | ||
| Reconstruction of genome-scale metabolic models for 126 human tissues using mCADRE | Q34509501 | ||
| Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease | Q34630137 | ||
| Implications of the dominant role of transporters in drug uptake by cells | Q34939329 | ||
| Modelling the heart: insights, failures and progress | Q35007351 | ||
| Diagnosing fatty liver disease: a comparative evaluation of metabolic markers, phenotypes, genotypes and established biomarkers | Q35018573 | ||
| Reconstruction and analysis of human kidney-specific metabolic network based on omics data | Q35040014 | ||
| Large-scale in silico modeling of metabolic interactions between cell types in the human brain | Q35117087 | ||
| Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk | Q35171570 | ||
| New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures | Q35213378 | ||
| Human fatty liver disease: old questions and new insights | Q35588477 | ||
| A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes | Q35832269 | ||
| The Edinburgh human metabolic network reconstruction and its functional analysis | Q36052649 | ||
| Large-scale prediction and testing of drug activity on side-effect targets | Q36059863 | ||
| The burden of overweight and obesity-related ill health in the UK. | Q36918217 | ||
| Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. | Q37121662 | ||
| Human metabolic network reconstruction and its impact on drug discovery and development | Q37158701 | ||
| Which in vitro models could be best used to study hepatocyte polarity? | Q37189719 | ||
| The virtual cell--a candidate co-ordinator for 'middle-out' modelling of biological systems | Q37416872 | ||
| Nutritional systems biology: definitions and approaches | Q37539998 | ||
| Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome | Q37693238 | ||
| From the metabolic syndrome to NAFLD or vice versa? | Q37703968 | ||
| Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. | Q37771540 | ||
| Current therapeutic strategies in non-alcoholic fatty liver disease. | Q37859419 | ||
| A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver | Q38105838 | ||
| Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population | Q39693472 | ||
| Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions | Q39924973 | ||
| Three-dimensional in vitro cell culture leads to a marked upregulation of cell function in human hepatocyte cell lines--an important tool for the development of a bioartificial liver machine | Q40940480 | ||
| Computational reconstruction of tissue‐specific metabolic models: application to human liver metabolism | Q41846171 | ||
| QSSPN: dynamic simulation of molecular interaction networks describing gene regulation, signalling and whole-cell metabolism in human cells | Q42862600 | ||
| Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis | Q43174499 | ||
| Integrating metabolic, transcriptional regulatory and signal transduction models in Escherichia coli. | Q43575020 | ||
| GEMSiRV: a software platform for GEnome-scale metabolic model simulation, reconstruction and visualization | Q43713406 | ||
| On the reconstruction of the Mus musculus genome-scale metabolic network model. | Q47853955 | ||
| The reconstruction and analysis of tissue specific human metabolic networks | Q48766685 | ||
| Epidemiology of non-alcoholic fatty liver disease. | Q51566234 | ||
| GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models | Q51847870 | ||
| Primary mouse hepatocytes for systems biology approaches: a standardized in vitro system for modelling of signal transduction pathways | Q51926243 | ||
| The virtual liver: a multidisciplinary, multilevel challenge for systems biology | Q52890211 | ||
| Emergence of the silicon human and network targeting drugs | Q57393826 | ||
| Snoopy--a unifying Petri net framework to investigate biomolecular networks | Q63241826 | ||
| Tuberculosis presenting as immune thrombocytopenic purpura | Q71595345 | ||
| Differential gene expression in periportal and perivenous mouse hepatocytes | Q79282635 | ||
| Network-based prediction of human tissue-specific metabolism | Q81798711 | ||
| Genome-scale modeling and in silico analysis of mouse cell metabolic network | Q82298733 | ||
| Maintaining hepatocyte differentiation in vitro through co-culture with hepatic stellate cells | Q83274871 | ||
| Liver biopsy | Q83395480 | ||
| P433 | issue | 41 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systems biology | Q815297 |
| metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
| fatty liver disease | Q6058862 | ||
| non-alcoholic fatty liver | Q66299798 | ||
| P304 | page(s) | 15070-15078 | |
| P577 | publication date | 2014-11-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Systems biology approaches for studying the pathogenesis of non-alcoholic fatty liver disease | |
| P478 | volume | 20 |
| Q47145823 | Computational Modeling in Liver Surgery |
| Q90601947 | Fagonia indica Repairs Hepatic Damage through Expression Regulation of Toll-Like Receptors in a Liver Injury Model |
| Q95940426 | From personalised nutrition to precision medicine: the rise of consumer genomics and digital health |
| Q92694745 | From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis |
| Q47158582 | Integration of Genome Scale Metabolic Networks and Gene Regulation of Metabolic Enzymes With Physiologically Based Pharmacokinetics |
| Q46443002 | Intermittent calorie restriction largely counteracts the adverse health effects of a moderate-fat diet in aging C57BL/6J mice |
| Q58417407 | Multi-scale, whole-system models of liver metabolic adaptation to fat and sugar in non-alcoholic fatty liver disease |
| Q36407635 | Synergistic interaction between lipid-loading and doxorubicin exposure in Huh7 hepatoma cells results in enhanced cytotoxicity and cellular oxidative stress: implications for acute and chronic care of obese cancer patients |
| Q27016052 | The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease |
Search more.